Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (56)

1

Letter to the Editor : indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

enthalten in: Journal of comparative effectiveness research | 2023

von Ballew, N. | Mian, A. | Levy, R. | +1

CommentOn: J Comp Eff Res. 2022 Jul;11(10):765-777. - PMID 35546484

2

Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis

enthalten in: British journal of clinical pharmacology | 2022

von Tran, L. | Yao, Z. | Xu, Z. | +1

3

Improvement of asymmetric thyroid eye disease with teprotumumab

enthalten in: The British journal of ophthalmology | 2022

von Ugradar, S. | Wang, Y. | Mester, T. | +2

4

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA) : an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial

enthalten in: BMJ open | 2022

von Li, R. | Liu, X. | Song, C. | +14

5

Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma : case series and systematic review

enthalten in: BMJ open ophthalmology | 2022

von Heng, J. | Kim, J. | Jones, D. | +7

6

Secukinumab-Induced Lymphocytic Colitis

enthalten in: Journal of investigative medicine high impact case reports | 2022

von Gandu, S. | Khan, M. | Vasikaran, A. | +1

7

Non-infective cystitis secondary to benralizumab immunotherapy

enthalten in: BMJ case reports | 2022

von Murray, T. | Haagsma, B. | Chetwood, A.

8

Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab

enthalten in: BMJ case reports | 2022

von Zand Irani, A. | Almuwais, A. | Gibbons, H.

9

Belimumab in childhood systemic lupus erythematosus : A review of available data

enthalten in: Frontiers in immunology | 2022

von Chen, F. | Zheng, Y. | Chen, X. | +4

10

Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms

enthalten in: Journal of Crohn's & colitis | 2021

von Ungar, B. | Malickova, K. | Hanžel, J. | +19

1
2
3
4
5
6
Nächster »
[6]